Ascend Advanced Therapies is a cutting-edge Gene to GMP (AAV) contract development and manufacturing organization (CDMO) that specializes in the development and production of life-changing therapies using viral vectors. With a team of over 120 industry veterans, Ascend combines expertise from the recent acquisition of Freeline Therapeutics in Munich and the clinical manufacturing group in Alachua, Florida, to enhance its capabilities in the Cell and Gene Therapy market. The company is committed to innovation, quality, and collaboration, aiming to establish a strong brand presence amidst a competitive landscape of over 50 rivals. Ascend Advanced Therapies is dedicated to advancing therapeutics and improving patient outcomes through its unique intellectual property and platform assets.